- $250.84m
- $234.90m
- $4.41m
Ocugen Q2 revenue beats estimates
Brief: Ocugen Q2 EPS USD -0.07
Ocugen Inc expected to post a loss of 5 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-SpaceX, Sandisk, Salesforce
U.S. STOCKS ON THE MOVE-SpaceX, Sandisk, Marvell Technology
U.S. STOCKS ON THE MOVE-American Express, Deckers, Q32 Bio
U.S. STOCKS ON THE MOVE-American Express, Deckers, Q32 Bio
Ocugen rises on Mideast licensing deal for experimental blindness gene therapy
Ocugen plunges after $115 million convertible bonds offering, bigger loss
Gene therapy firm Ocugen's Q1 revenue beats, extends cash runway to 2028
Brief: Ocugen, Inc. Announces Pricing Of $115 Million Of 6.75% Convertible Senior Notes
Brief: Ocugen Q1 EPS USD -0.06
U.S. STOCKS ON THE MOVE-Eli Lilly, Space stocks, Anixa Biosciences
U.S. STOCKS ON THE MOVE-Intel, Tempus AI, Boeing
U.S. STOCKS ON THE MOVE-Cal-Maine, Rivian, Alkermes
U.S. STOCKS ON THE MOVE-Seagate, nCino, Zymeworks
Ocugen rises after finishing patient dosing in late-stage eye gene therapy trial
U.S. STOCKS ON THE MOVE-Dollar General, software stocks, Sable Offshore
U.S. STOCKS ON THE MOVE-FedEx, Estee Lauder, Janus Henderson